University of California, Davis
ucdavis.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
800
Active
193
Phase 3
19
Total enrollment
3,622,071
Pipeline matrix
Showing 40 of 92 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Reduction in antimetabolite immunosuppression | — | — | — | — | — | 1 | |
| 5Fluorouracil | — | — | — | — | — | 1 | |
| Ropivacaine Continuous Infusion Catheter | — | — | — | — | — | 1 | |
| Single Dose Liposomal Bupivicaine | — | — | — | — | — | 1 | |
| Magnesium Sulfate in Parenteral Dosage Form | — | — | — | — | — | 1 | |
| Normal saline placebo | — | — | — | — | — | 1 | |
| Neurontin | — | — | — | — | — | 1 | |
| Dilaudid Injectable Product | — | — | — | — | — | 1 | |
| Marcaine Injectable Product | — | — | — | — | — | 1 | |
| Oxycodone Hydrochloride | — | — | — | — | — | 1 | |
| Hycet 7.5Mg-325Mg/15Ml Solution | — | — | — | — | — | 1 | |
| Zofran | — | — | — | — | — | 1 | |
| Scopolamine patch | — | — | — | — | — | 1 | |
| Ativan | — | — | — | — | — | 1 | |
| Flexeril Oral Product | — | — | — | — | — | 1 | |
| Tylenol Suspension | — | — | — | — | — | 1 | |
| Modafinil | — | — | — | — | — | 1 | |
| Dopamine administration | — | — | — | — | — | 1 | |
| Norepinephrine | — | — | — | — | — | 1 | |
| Hydroquinone Topical | — | — | — | — | — | 1 | |
| Gabapentin | — | — | — | — | — | 2 | |
| Transnasal sphenopalatine ganglion block | — | — | — | — | — | 1 | |
| Oxybutynin Transdermal Patch | — | — | — | — | — | 1 | |
| Oral Oxybutynin | — | — | — | — | — | 1 | |
| Rituximab | — | — | — | — | — | 5 | |
| Prednisone | — | — | — | — | — | 3 | |
| Ibrutinib | — | — | — | — | 4 | ||
| Carboplatin | — | — | — | — | 3 | ||
| Etoposide | — | — | — | — | 3 | ||
| oxaliplatin | — | — | — | — | 3 | ||
| Doxycycline | — | — | — | — | 2 | ||
| Bendamustine Hydrochloride | — | — | — | — | 2 | ||
| Gemcitabine | — | — | — | — | — | 2 | |
| Pneumovax-23 | — | — | — | — | — | 1 | |
| Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy | — | — | — | — | — | 1 | |
| Abiraterone | — | — | — | — | — | 1 | |
| Darolutamide | — | — | — | — | — | 1 | |
| Brentuximab Vedotin | — | — | — | — | — | 1 | |
| Tart Cherry Juice | — | — | — | — | — | 1 | |
| Obinutuzumab | — | — | — | — | — | 1 |
52 more active programs hidden
Next readouts
- 2025-08-14
- 2026-03-09
- 2026-06
- 2026-06-24
- 2026-07
- 2026-07
- 2026-07
- 2026-07-01
- 2026-07-01
- 2026-08-01
Top conditions
- Healthy26
- Obesity20
- Breast Cancer17
- Unspecified Adult Solid Tumor, Protocol Specific14
- Lung Cancer13
- Prostate Cancer13
- Metabolic Syndrome10
- Inflammation9
Frequently asked questions about University of California, Davis
- How many clinical trials does University of California, Davis have on ClinicalTrials.gov?
- University of California, Davis is listed as the lead sponsor on 800 clinical trials in ClinicalTrials.gov, 193 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of California, Davis's trials are in Phase 3?
- 19 of University of California, Davis's trials are in Phase 3, spread across 92 active drug programs.
- What therapeutic areas does University of California, Davis focus on?
- University of California, Davis's most-studied conditions on ClinicalTrials.gov are Healthy, Obesity, Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Lung Cancer.
- When are University of California, Davis's next clinical trial readouts?
- University of California, Davis has 10 upcoming primary-completion readouts tracked here; the soonest is “Imaging of Neuro-Inflammation and the Risk for Post-Traumatic Epilepsy”, expected around 2025-08-14.